Drugs
Cure8 research brief
Why This Matters
Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer evidence about antibiotic-sparing treatments and long-term management.
Who Should Pay Attention
Adult patients with an ileal pouch (post-surgery patients), clinicians who manage pouchitis, and researchers studying pouch inflammation or antibiotic-sparing therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article (abstract) outlines that probiotics are recommended in selected patients for prevention, while several advanced therapies approved for ulcerative colitis and Crohn's disease are being used off-label or in practice for chronic pouchitis.
Vedolizumab is noted as approved in Europe specifically for chronic pouchitis; evidence for anti-TNF agents, ustekinumab, IL-23p19 antagonists, and JAK inhibitors comes mainly from observational and real-world data rather than controlled trials.
The review also describes fecal microbiota transplantation as investigational with inconsistent early results, and highlights that dietary patterns may influence pouch inflammation though evidence is mainly observational.
Overall, the authors call for well-designed prospective and controlled studies to define antibiotic-sparing strategies, optimal treatment sequencing, and durability of response. This summary is grounded in the source-provided abstract.
Keep In Mind
This entry is based on the article abstract; the abstract summarizes current practice and research gaps but does not provide detailed trial results. Vedolizumab is highlighted as having regulatory approval in Europe for chronic pouchitis; other advanced therapies are supported mainly by observational data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDrugs
AuthorsIlaria Faggiani, Connor Tuttle, Silvio Danese +6 more
InstitutionDepartment of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, 20132, Milan, Italy.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 16, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Conflict of interest: I.F. and C.T. have no conflicts to declare; S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor. L.P-B. Declares consulting for: Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Banook, BMS, Boehringher, Celltrion, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, Hemay, Iterative Health, Janssen, Lilly, LifeMine, Luzsana, Medac, Mirador, Morphic, MSD, Nordic Pharma, Novartis, Oddifact, Oncodesign Precision Medicine, Coultreon (ex-Onco3R), ONO Pharma, OSE Immunotherapeuthics, Palisade Bio, Par’ Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, and Ventyx. Stock options: Iterative Health, Oragen, and Pharmanest. Thetis lecture: Abbvie, Alfasigma, Amgen, Biogen, Celltrion, Dr Falk, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Takeda, and Tillots. V.J. has received consulting/advisory board fees from AbbVie, Alimentiv, Asieris, AstraZeneca, Attovia, Biomebank, Boehringer Ingelheim, Caldera Therapeutics, Calluna, Celltrion, Domain Therapeutics, Eli Lilly, Enthera, Ensho, Exeliom Biosciences, Ferring Ventures, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Granite Bio, Janssen, Merck, Metacrine, Mountainfield, MRM Health, Nxera, Organon, OSE Immunotherapeutics, Pandion, Pendopharm, Pfizer, Prometheus Biosciences, Roche, Salvina, Sanofi, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Thabor Therapeutics, Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, and Zealand. Pharma speaker’s fees from, Abbvie, Ferring, Eli Lilly, Pfizer, and Takeda. R.S. has received consulting fees from: AbbVie, Alimentiv, Pendopharm, and Takeda. I.D. declares fees for consultation, advisory boards, honoraria for speaking and teaching, royalties, or grant support from Abbvie, Altman Research, AstraZeneca, BMS, Celltrion, Eli-Lilly, Falk Pharma, Ferring, Gilead, Galapagos, Roche/Genentech, Harp Dx, Janssen, Pfizer, Prometheus Biosciences, Sandoz, Sangamo, Spyre Therapeutics, and Takeda. R.P. is a consultant for: Abbott, AbbVie, Abbivax, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Inviva, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mirador, Novartis, Oppilan Pharma, Odyssey, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Satisfai Health, Shire, Sublimity Therapeutics, Spyre Therapeutics, Takeda Pharmaceuticals, Teva, Tillots, Trellus, Union Biopharma, Viatris, Ventyx, and UCB. Speaker’s Fees for: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, and Takeda. Pharmaceuticals Advisory Boards for: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Sublimity Therapeutics, Takeda Pharmaceuticals, and Ventyx. C.M. has recieved consulting fees: AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Forte Biosciences, Fresenius Kabi, Gilead, Janssen, McKesson, Mirador Therapeutics, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc, Roche, Sanofi, Takeda, and Tillotts Pharma. Speaking fees: AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Merck, Organon, Pendopharm, Pfizer, Sanofi, Takeda, and Tillotts Pharma. Royalties: Springer Publishing research support from AbbVie, Eli Lilly, Ferring, and Pfizer. Author Contributions: I.F.: writing original draft, review, and editing, C.T.: writing original draft, review, and editing, S.D.: writing, review, and editing, L.P-B.: writing, review, and editing, V.J.: writing, review, and editing, R.S.: writing, review, and editing, I.D.: writing, review, and editing, R.P.: writing, review, and editing, C.M.: conceptualization, writing, review, and editing. All authors have read and approved the final version of the manuscript and agree to be accountable for the work. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Availability of data and materials: Not applicable. Code availability: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Management of Arthritis Associated with Inflammatory Bowel Disease (IBD): A Systematic Review of Conventional and Targeted Therapies
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.
This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.
Postoperative Complications Associated with Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.